City National Bank of Florida MSD Invests $229,000 in HCA Healthcare, Inc. (NYSE:HCA)

City National Bank of Florida MSD bought a new position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 762 shares of the company's stock, valued at approximately $229,000.

Several other large investors have also recently modified their holdings of the stock. Congress Wealth Management LLC DE boosted its stake in shares of HCA Healthcare by 3.4% in the fourth quarter. Congress Wealth Management LLC DE now owns 1,039 shares of the company's stock worth $312,000 after acquiring an additional 34 shares during the period. Evergreen Private Wealth LLC boosted its stake in HCA Healthcare by 0.3% in the 4th quarter. Evergreen Private Wealth LLC now owns 12,787 shares of the company's stock worth $3,838,000 after purchasing an additional 35 shares during the period. Mediolanum International Funds Ltd raised its position in shares of HCA Healthcare by 0.3% during the fourth quarter. Mediolanum International Funds Ltd now owns 10,592 shares of the company's stock valued at $3,153,000 after buying an additional 36 shares during the last quarter. Prairie Wealth Advisors Inc. grew its stake in HCA Healthcare by 6.1% during the fourth quarter. Prairie Wealth Advisors Inc. now owns 700 shares of the company's stock valued at $210,000 after acquiring an additional 40 shares in the last quarter. Finally, Whittier Trust Co. lifted its stake in HCA Healthcare by 3.6% in the 4th quarter. Whittier Trust Co. now owns 1,195 shares of the company's stock worth $359,000 after purchasing an additional 41 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company's stock.

HCA Healthcare Stock Performance

Shares of HCA opened at $376.53 on Friday. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $417.14. The stock has a fifty day moving average price of $345.81 and a 200-day moving average price of $329.37. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. The firm has a market cap of $90.58 billion, a PE ratio of 17.14, a P/E/G ratio of 1.10 and a beta of 1.46.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.75 by $0.70. The firm had revenue of $18.32 billion for the quarter, compared to the consensus estimate of $18.26 billion. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. The company's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.36 earnings per share. Equities research analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 16th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Monday, June 16th. This represents a $2.88 dividend on an annualized basis and a yield of 0.76%. HCA Healthcare's dividend payout ratio is currently 12.81%.

Insider Activity

In related news, COO Jon M. Foster sold 15,698 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $369.32, for a total value of $5,797,585.36. Following the transaction, the chief operating officer now owns 12,646 shares in the company, valued at approximately $4,670,420.72. This represents a 55.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

HCA has been the topic of a number of research analyst reports. Guggenheim started coverage on HCA Healthcare in a research report on Wednesday, April 9th. They issued a "neutral" rating on the stock. Royal Bank of Canada lowered their target price on HCA Healthcare from $384.00 to $376.00 and set an "outperform" rating for the company in a research report on Monday, April 28th. Robert W. Baird reaffirmed a "neutral" rating and set a $336.00 price target (down previously from $396.00) on shares of HCA Healthcare in a research note on Tuesday, April 15th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $405.00 price objective on shares of HCA Healthcare in a research note on Monday, January 27th. Finally, Bank of America dropped their price target on shares of HCA Healthcare from $380.00 to $370.00 and set a "buy" rating for the company in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $381.13.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.